Home
RNA Therapeutics USA
October 23 - October 24, 2024
RNA Therapeutics USA

SAE Media Group’s 2nd Annual Conference
RNA Therapeutics USA
23-24 October, 2024 | Boston, MA, USA
-------------------------------------------------------------------------
SAE Media Group is proud to announce the 2nd annual RNA Therapeutics USA Conference taking place in Boston on the 23 – 24th October 2024.

As part of SAE Media Group’s leading portfolio of Drug Discovery and the long-standing RNA Therapeutics Europe conferences, we are delighted to introduce RNA Therapeutics USA.

RNA therapies are leading the way in the field of genetic medicine, with the market expected to reach 1.81 billion USD by 2025, growing at a CAGR of 7.5%. This in large can be attributed to the topical advancements in mRNA vaccines, paving the way for global regulatory successes.

We currently see the RNA Therapeutic field focus on the challenges associated with delivery of RNA molecules extrahepatically, with a particular drive to overcome barriers of delivery to the Central Nervous System. In addition, RNA technologies continue to lead the way in revolutionising immunotherapies and the vaccine landscape, along with exceptional potential to treat a wide variety of chronic, previously undruggable diseases. The 2024 agenda will address these latest challenges along with recent advancements in RNAi and continue to drive innovation in the field of RNA Therapeutics.

Don't miss this opportunity to network with the pharma and biotech community of global experts; the two-day agenda offers you peer-to-peer networking with Directors of novel RNA therapies, CEOs, Senior and expert scientists, Chief Medical Officers, Senior Vice Presidents and many more.

FEATURED SPEAKERS

Jay Sarkar

Jay Sarkar

Researcher and Entrepreneur, Stanford University
Kinkini Roy

Kinkini Roy

Associate Director, Aviceda Therapeutics
Martin Akerman

Martin Akerman

CTO & Co-Founder, Envisagenics
Neil Robertson

Neil Robertson

Principal Scientist, TransCode Therapeutics, Inc.
Richard Geary

Richard Geary

EVP, Chief Development Officer, Ionis Pharmaceuticals, Inc.
Sourav Choudhury

Sourav Choudhury

Head AAV Technologies, Sanofi
Zimeng Wang

Zimeng Wang

Senior Scientist, AstraZeneca

Confirmed Representative

, BioPhorum
Confirmed Representative

Hetal Patel

Senior Principle Scientist/Group Leader, Pfizer
Hetal Patel

Jay Sarkar

Researcher and Entrepreneur, Stanford University
Jay Sarkar

Dr. Sarkar is a researcher and entrepreneur with a background in applied physics and electrical engineering, which he utilizes to develop systems biology solutions for medicine. He built his first company off his foundational PhD work at Stanford University, where he pioneered the use the mRNA modality for transiently reprogramming cell epigenetics to specifically reset cellular age. The approach has grown as one of the hottest in the longevity community, with some of the largest startup investments in biotech history. He has now progressed to studying the broader problem of new modality integration and distribution in a variety of tissues.

Kinkini Roy

Associate Director, Aviceda Therapeutics
Kinkini Roy

After finishing PhD and postdoc study from University of Massachusetts Amherst, Kinkini Roy worked in industry for last 12 years in Boston Biotech as well as big corporation. Currently she is leading the program for the next-generation RNA therapeutics using a proprietary synthetic, high-affinity, multi-valent glycans that target extrahepatic cells and improve intracellular delivery and efficacy of siRNA, Anti- sense oligonucleotides, mRNA-based therapeutics, Crispr-Cas9 gene editing and lysosomal targeted protein degradation. Along with that she is leading the formulation development team and develop the formulation development strategy for pipeline development.

Martin Akerman

CTO & Co-Founder, Envisagenics
Martin Akerman

Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.

Neil Robertson

Principal Scientist, TransCode Therapeutics, Inc.
Neil Robertson

Dr. Neil Robertson is a Principal Scientist at TransCode Therapeutics. His research is focused on the application of material science to solve biomedical questions and limitations. Over his career, he has advanced the field of material science for nucleic acid delivery with specific relevance to cancer. His expertise lies in the design and use of novel nanoparticle platforms for the detection and treatment of human pathologies in various disease models. His research is focused on the development of novel nanoparticle constructs for the detection and treatment of cancer. By building on past work and designing new iron oxide nanoparticles, he aims to more precisely target tumor tissue of interest. His goal is to create novel multi-modal imaging constructs which can be useful for both researchers and clinicians. Dr. Robertson received his Ph.D. in Chemistry from the University at Albany, SUNY under the guidance of Prof. Mehmet Yigit and his B.S. in Biochemistry from the University at Buffalo, SUNY.

Richard Geary

EVP, Chief Development Officer, Ionis Pharmaceuticals, Inc.
Richard Geary

Dr. Geary is the Executive Vice President and Chief Development Officer at Ionis Pharmaceuticals. He is responsible for preclinical development, clinical development and clinical-stage manufacturing for Ionis’ antisense medicines. Since joining Ionis in 1995, Dr. Geary has been involved in discovery and development including the regulatory submission of more than 50 investigational new drug applications to U.S. and other regulatory agencies. In his position as head of development, Dr. Geary has led six successful antisense medicine development programs through approvals in multiple jurisdictions.
During his tenure at Ionis, he has authored or co-authored 14 book chapters and more than 80 peer-reviewed manuscripts.
 

Sourav Choudhury

Head AAV Technologies, Sanofi
Sourav Choudhury

Sourav Choudhury is a Lab Head in the Genomics Medicine Unit at Sanofi, based in Framingham, MA. He joined Sanofi in 2020 to lead AAV Technologies Laboratory, a platform group focused on AAV capsid engineering and AAV immunology.
Sourav obtained his Ph.D. from UMASS Medical School for his work on development of novel CNS-tropic AAV capsids. He did his postdoctoral training in the laboratory of Feng Zhang at Broad Institute, demonstrating the first in vivo application of CRISPR nuclease Cas12a. Sourav has since worked in Cambridge-based early stage biotechs, first at Intellia Therapeutics designing AAV-based genome editing tools, and then at LogicBio Therapeutics, where he led early-discovery stage indication selection.
 

Zimeng Wang

Senior Scientist, AstraZeneca
Zimeng Wang

sponsors


BioPhorum
Senior Principle Scientist/Group Leader
Pfizer
Researcher and Entrepreneur
Stanford University
Associate Director
Aviceda Therapeutics
CTO & Co-Founder
Envisagenics
Principal Scientist
TransCode Therapeutics, Inc.
EVP, Chief Development Officer
Ionis Pharmaceuticals, Inc.
Head AAV Technologies
Sanofi
Senior Scientist
AstraZeneca

Exhibitors

Supporters

VENUE

Courtyard by Marriott Boston Downtown

Boston, USA

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

Exhibitors


ChemGenes

Exhibitors
http://www.chemgenes.com

ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. Additionally, ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.

Media Partners


pharmaphorum

Supporters
http://www.pharmaphorum.com

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


The Medicine Maker

Supporters
https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo

The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Courtyard by Marriott Boston Downtown


USA

Courtyard by Marriott Boston Downtown

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download

Title


Description

Download

Title


Description


Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SAE Media Group

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smgconferences.com Email: events@saemediagroup.com
Registered in England - SMi Group Ltd trading as SAE Media Group




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SAE Media Group.
Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

Fill in your details to download the brochure

By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.